Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to ma...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | BMC Cancer |
Online Access: | https://doi.org/10.1186/s12885-022-09576-3 |
_version_ | 1811289225464643584 |
---|---|
author | Apostolos Tsiachristas Grant Vallance Rositsa Koleva-Kolarova Harriet Taylor Luke Solomons Giovanni Rizzo Catherine Chaytor Junel Miah Sarah Wordsworth A. Bassim Hassan |
author_facet | Apostolos Tsiachristas Grant Vallance Rositsa Koleva-Kolarova Harriet Taylor Luke Solomons Giovanni Rizzo Catherine Chaytor Junel Miah Sarah Wordsworth A. Bassim Hassan |
author_sort | Apostolos Tsiachristas |
collection | DOAJ |
description | Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to match 466 patients tested with ToxNav® with 1556 patients from a historical cohort, and performed regression analysis to estimate the impact of ToxNav®on toxicity, depression, and hospital costs. Results ToxNav® appeared to reduce the likelihood of experiencing moderate (OR: 0.59; 95%CI: 0.45–0.77) and severe anaemia (OR: 0.55; 95%CI: 0.33–0.90), and experience of pain for more than 4 days a week (OR: 0.50; 95%CI: 0.30–0.83), while it increased the likelihood of mild neutropenia (OR: 1.73; 95%CI: 1.27–2.35). It also reduced the cost of chemotherapy by 12% (95%CI: 3–31) or £9765, the cost of non-elective hospitalisation by 23% (95%CI: 8–36) or £2331, and the cost of critical care by 21% (95%CI: 2–36) or £1219 per patient. For the DPYD variant associated with critical risk of toxicity (rs3918290), the improved non-elective hospital costs were > £20,000, whereas variants associated with hand-foot syndrome toxicity had no detectable cost improvement. Conclusion Upfront testing of DPYD variants appears to reduce the toxicity burden of Capecitabine and 5-FU in cancer patients and can lead to substantial hospital cost savings, only if the dose management of the drugs in response to variants detected is standardised and regulated. |
first_indexed | 2024-04-13T03:51:09Z |
format | Article |
id | doaj.art-58f8ffe3049c47f5a849a3e126d1d17d |
institution | Directory Open Access Journal |
issn | 1471-2407 |
language | English |
last_indexed | 2024-04-13T03:51:09Z |
publishDate | 2022-04-01 |
publisher | BMC |
record_format | Article |
series | BMC Cancer |
spelling | doaj.art-58f8ffe3049c47f5a849a3e126d1d17d2022-12-22T03:03:49ZengBMCBMC Cancer1471-24072022-04-0122111110.1186/s12885-022-09576-3Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsApostolos Tsiachristas0Grant Vallance1Rositsa Koleva-Kolarova2Harriet Taylor3Luke Solomons4Giovanni Rizzo5Catherine Chaytor6Junel Miah7Sarah Wordsworth8A. Bassim Hassan9Nuffield Department of Population Health, University of OxfordOxford University Hospitals NHS TrustNuffield Department of Population Health, University of OxfordOxford University Hospitals NHS TrustOxford University Hospitals NHS TrustOxford University Hospitals NHS TrustOxford University Hospitals NHS TrustOxford University Hospitals NHS TrustNuffield Department of Population Health, University of OxfordOxford University Hospitals NHS TrustAbstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to match 466 patients tested with ToxNav® with 1556 patients from a historical cohort, and performed regression analysis to estimate the impact of ToxNav®on toxicity, depression, and hospital costs. Results ToxNav® appeared to reduce the likelihood of experiencing moderate (OR: 0.59; 95%CI: 0.45–0.77) and severe anaemia (OR: 0.55; 95%CI: 0.33–0.90), and experience of pain for more than 4 days a week (OR: 0.50; 95%CI: 0.30–0.83), while it increased the likelihood of mild neutropenia (OR: 1.73; 95%CI: 1.27–2.35). It also reduced the cost of chemotherapy by 12% (95%CI: 3–31) or £9765, the cost of non-elective hospitalisation by 23% (95%CI: 8–36) or £2331, and the cost of critical care by 21% (95%CI: 2–36) or £1219 per patient. For the DPYD variant associated with critical risk of toxicity (rs3918290), the improved non-elective hospital costs were > £20,000, whereas variants associated with hand-foot syndrome toxicity had no detectable cost improvement. Conclusion Upfront testing of DPYD variants appears to reduce the toxicity burden of Capecitabine and 5-FU in cancer patients and can lead to substantial hospital cost savings, only if the dose management of the drugs in response to variants detected is standardised and regulated.https://doi.org/10.1186/s12885-022-09576-3 |
spellingShingle | Apostolos Tsiachristas Grant Vallance Rositsa Koleva-Kolarova Harriet Taylor Luke Solomons Giovanni Rizzo Catherine Chaytor Junel Miah Sarah Wordsworth A. Bassim Hassan Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients BMC Cancer |
title | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients |
title_full | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients |
title_fullStr | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients |
title_full_unstemmed | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients |
title_short | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients |
title_sort | can upfront dpyd extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy a propensity score matched analysis of 2022 uk patients |
url | https://doi.org/10.1186/s12885-022-09576-3 |
work_keys_str_mv | AT apostolostsiachristas canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT grantvallance canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT rositsakolevakolarova canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT harriettaylor canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT lukesolomons canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT giovannirizzo canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT catherinechaytor canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT junelmiah canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT sarahwordsworth canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients AT abassimhassan canupfrontdpydextendedvarianttestingreducetoxicityandassociatedhospitalcostsoffluoropyrimidinechemotherapyapropensityscorematchedanalysisof2022ukpatients |